Clinical trials
HIV clinical trials
Below are recruiting hiv clinical trials, each written for real people, not researchers. We’re tracking 611 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07209917Recruiting
Cervical cancer prevention for women with HIV and HPV
This trial tests a new way to prevent cervical cancer in women with both HIV and HPV. It focuses on women in India who are already on stable HIV treatment and have a normal cervical exam.
Bangalore, KarnatakaAges 25–50 - NCT07737340Recruiting
Metabolic liver disease in new HIV patients
This study looks at liver health in people newly diagnosed with HIV, before they start HIV treatment. It aims to understand early changes in the liver related to metabolism.
Ankara, AnkaraAges 18 years+ - NCT07728123Recruiting
Screen2Prevent for young people in the ED
This trial is testing a prevention strategy for young people who come to the emergency department. It aims to find better ways to screen and prevent health problems early on.
Tampa, FloridaAges 14–24 - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT07076043RecruitingPhase 4
HIV prevention for young women getting reproductive health care
This study offers different forms of HIV prevention medicine (PrEP) to young women ages 18–30 who are visiting clinics for reproductive health services like family planning or postnatal care. It aims to see which delivery method works best for you.
Thika, Kiambu CountyAges 18–30 - NCT07707778Enrolling by invitationPhase 4
Tirzepatide for Weight and Aging in People with HIV
This trial tests whether a weight-loss medicine called tirzepatide can slow biological aging and improve metabolism in people with HIV who are already on effective treatment. It may help you reduce weight and possibly reverse some signs of aging.
TaipeiAges 18 years+ - NCT07704164RecruitingPhase 2
Colchicine to lower heart artery swelling in HIV
This trial tests if colchicine, a medicine for inflammation, can reduce swelling in the heart arteries of people with HIV. It may help lower the risk of heart problems in those already on a statin or similar medication.
BarcelonaAges 50 years+ - NCT03132311RecruitingPhase 4
Yellow fever vaccine study for certain people with HIV
This trial checks whether a yellow fever vaccine is safe and works well in adults with HIV who have relatively healthy immune function. It may help doctors understand the best way to protect people with HIV who have never had this vaccine.
Rio de JaneiroAges 18–59 - NCT03413683Recruiting
Studying frailty in older adults living with HIV
This study looks at frailty (feeling weak, having trouble with daily activities, or losing strength) in people age 50 and older who are living with HIV. It may help researchers understand frailty in HIV and how to better support older adults.
ShatinAges 50 years+ - NCT03684655RecruitingPhase 2
PET-MR scan study of immune activity in people with HIV
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
San Francisco, CaliforniaAges 18 years+ - NCT03729752RecruitingPhase 1
PET scan to study an HIV-fighting antibody in the body
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
San Francisco, CaliforniaAges 18 years+ - NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT04142047Recruiting
Study muscle energy and fatigue in older adults
This study measures how older adults’ muscles use energy and how easily they tire during activity. It includes both people with HIV (with stable treatment and an undetectable viral load) and people without HIV to better understand differences in fatigue.
Baltimore, MarylandAges 60–90 - NCT04160455Recruiting
Study of GALIG proteins in adults with HIV on or off treatment
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
OrléansAges 18 years+ - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT04430257Recruiting
PrEP for people at higher risk of HIV
This study checks whether taking HIV prevention medicine called PrEP can help protect people who are not living with HIV but have recent risk of HIV exposure. You may qualify if you have ongoing risk and are not already taking PrEP.
Cambridge, MassachusettsAges 18 years+ - NCT04513626RecruitingPhase 2
HIV trial testing doravirine plus raltegravir in adults
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
Paris, Île-de-France RegionAges 18 years+ - NCT04577313Recruiting
Study to improve HIV medicine adherence reminders
This study looks at a way to help people take their HIV medicines as prescribed. It focuses on people who are HIV-positive and not currently taking their treatment consistently.
Storrs, ConnecticutAges 18 years+ - NCT04648046RecruitingPhase 1/Phase 2
CAR-T cell treatment for HIV infection
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
Sacramento, CaliforniaAges 18–65 - NCT04653610Recruiting
Study immune signals in untreated HIV using extra samples
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
Ghent, Oost-VlaanderenAges 18–65 - NCT04725617Recruiting
Smoking-quit program for people with HIV and sleep issues
This study tests a wellness-based smoking-cessation program (including the stop-smoking medicine varenicline) for people living with HIV who want to quit. It aims to help you reduce or stop smoking while monitoring safety, sleep, and mental health during the program.
Phoenix, ArizonaAges 18–75 - NCT04810858Recruiting
Study how chronic marijuana affects brain inflammation in HIV
This study looks at whether ongoing marijuana use changes “brain inflammation” and brain cell injury in people living with HIV. It may help researchers understand potential risks or protective effects and how treatment and brain health interact.
Winston-Salem, North CarolinaAges 25–59 - NCT04855773Recruiting
Mobile text-message support to help people stay on PrEP
This trial tests whether phone-based (iPhone/Android) text-message support can improve how consistently people use PrEP, an HIV prevention medicine. It may help you stay on track with refills and clinic visits, especially if you’re at higher risk of stopping PrEP.
San Francisco, CaliforniaAges 15 years+
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv?
- Yes. Clin2 currently lists 611 recruiting hiv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.